EBS - Emergent BioSolutions Inc.

NYSE - NYSE Delayed Price. Currency in USD

Emergent BioSolutions Inc.

400 Professional Drive
Gaithersburg, MD 20879
United States
240-631-3200
http://www.emergentbiosolutions.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees1,256

Key Executives

NameTitlePayExercisedYear Born
Mr. Fuad El-HibriFounder & Exec. Chairman1.03M1.71M1958
Mr. Daniel J. Abdun-NabiCEO & Director1.63M2.63M1955
Mr. Robert G. Kramer Sr.Pres & COO881.34kN/A1957
Mr. Atul SaranExec. VP of Corp. Devel., Gen. Counsel & Corp. Sec.659.71kN/A1973
Mr. Adam R. HaveyExec. VP of Bus. Operations722k264.54k1971
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The company offers BioThrax, an anthrax vaccine; ACAM2000, a Smallpox Vaccine; Raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. It also provides reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. The company's product candidates include NuThrax, a next generation anthrax vaccine; VLA1601, for the treatment of Zika virus; UNI-FLU, an influenza vaccine; EBX-205, an oral therapeutic to treat acute bacterial skin and skin structure infection; GC-072 for treating Burkholderia pseudomallei infection; EBI-001, a pan respiratory antiviral; FLU-IG (NP025) for the treatment of seasonal influenza; ZIKA-IG (NP024) for Zika infections; and FILOV (NP026) for treating treat hemorrhagic fever caused by Filoviruses. In addition, it provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.

Corporate Governance

Emergent BioSolutions Inc.’s ISS Governance QualityScore as of November 1, 2018 is 4. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 7; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.